Urge your members of Congress to support continued medical research funding
ASH will recognize Stanley Schrier, MD, a past ASH president and formerly Professor Emeritus of Medicine in Hematology at Stanford School of Medicine in Stanford, California, with the 2019 Exemplary Service Award for his exceptional years of service and dedication to ASH and to hematology.
Among patients with multiple myeloma, African Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances. The study found that on average it took about three months for white patients to start novel therapy after diagnosis, while for both African Americans and Hispanics it took about five months.
Yesterday, ASH President Roy Silverstein, MD, of the Medical College of Wisconsin asked members of the United States Senate Committee on Appropriations to adopt the provision in the House-passed fiscal year (FY) 2020 Labor, Health and Human Services, Education, and Related Agencies appropriations bill that dedicates $2 million for a federal program to collect data on the complications, treatments, and health outcomes of people with sickle cell disease (SCD).
Over half of people prescribed the targeted blood cancer-fighting drug ibrutinib developed new or worsened high blood pressure within six months of starting the medication, according to a new study published online today in Blood.
ASH has announced the names of 19 investigators who have each been awarded $150,000 through the ASH Bridge Grant Program in 2019.
Today, the American Board of Internal Medicine (ABIM) announced a significant change to its Maintenance of Certification (MOC) standards.
The Centers for Medicare and Medicaid Services (CMS) yesterday announced that it will cover CAR T-cell therapy (CAR-T) for Medicare beneficiaries as long as certain criteria are met.
New data suggest that people who have a parent, sibling, or child with blood cancer have a higher likelihood of being diagnosed with the disease.
FY 2020 Inpatient Prospective Payment System final rule does not take all steps needed to help institutions providing potentially curative cell therapies
Today Congress passed the Bipartisan Budget Act of 2019. The measure will avoid catastrophic cuts to essential discretionary spending programs and instead increase fiscal year (FY) 2020 non-defense discretionary spending by roughly $27 billion over current levels.
Urge your members of Congress to support continued medical research funding.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology